登录

iGeneTech Closes 50 Million Yuan Series B Round, Led by JC Capital

作者: Mailman 2019-08-31 23:18
艾吉泰康
http://www.igenetech.com
企业数据由 动脉橙 提供支持
基因检测产品开发商 | B轮 | 运营中
中国-北京
2019-08-28
融资金额:RMB¥5000万
金科君创资本
查看

According to VCbeat, on August 28, 2019, iGeneTech announced that it had completed the B round financing of 50 million yuan. This round of financing was led by JC Capital, which focuses on the investment of innovation-driven technology enterprises, followed by Legend Star and other current investors.


This round of funds will mainly be used to promote the commercialization of the technology platform, accelerate the distribution of sales in the domestic market and expand the business.


Founded in 2014, iGeneTech is a high-tech enterprise driven by gene testing technology located in Beijing Zhongguancun Life Science Park. The company focuses on the R&D and innovation of high-throughput sequencing targeted capture technology and the design and production of gene testing products. 


Based on two sets of intellectual properties of liquid probe capture (TargetSeq ®) and multiplex PCR amplification capture (MultipSeq ®), iGeneTech formed a system of diversified products containing gene capture reagents and kits, capture sequencing solution, synthetic biology. It is committed to promoting the transformation and application of the target capture technology in multiple fields, such as precision medical, scientific research, health, agriculture, hygiene and forensic.


So far, iGeneTech has provided hundreds of sequencing enterprises, thousands of doctors and scientific research workers with high-quality, efficient and cost-intensive customized kits and genetic testing solutions.


This latest round brings iGeneTech’s total backing to more than 100 million yuan. It got support from PWC capital, Zhongguancun Development Group and other investment companies. As a rarely "made in China" brand in the NGS upstream field, iGeneTech has great reputation in the industry.


>>>>

About JC Capital


Founded in January 2014, JC Capital is a venture capital institution specialized in early and mid-term technology investment. It mainly invests in innovative technology enterprises and pays attention to the business model of them. At present, JC Capital totally manages 3 funds with a duration of 8+2 years. By the end of 2018, it had invested in more than 40 companies.


>>>>

About Legend Star


Legend Star helps entrepreneurs create great businesses through investments, CEO training sessions, and an entrepreneurs alliance.


Since 2008, Legend Star has incubated and invested in nearly 600 companies and is deeply integrated into the Chinese entrepreneurial ecosystem.


Legend Star is the independent early-stage investment arm of Legend Holdings. Legend Holdings is the parent company of Lenovo, Raycom Real Estate, Joyvio Agribusiness and a large range of fast-growing Chinese companies.

相关赛道 IVD
文章标签 生物技术基因
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

打破空间转录组技术垄断,百迈客生物发布国内首款亚细胞级微孔空间芯片

纽伦捷生物完成千万级人民币天使轮融资,致力于新型基因治疗药物的研发

【首发】安吉康尔完成1亿元B轮融资,加速推进基因组疾病创新诊疗

【首发】杰毅生物完成近亿元首轮融资,用NGS和CRISPR技术革新病原微生物传统检测

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

​Nuanwa Technology Obtained 100 Million Yuan Angel Round Financing, To Explore in Health Insurance Business

2019-08-31
下一篇

守护母婴健康,小豆苗专家团全国公益巡讲重庆站活动圆满举办

2019-09-01